1.
Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections.
Najafi, S, Tan, SC, Aghamiri, S, Raee, P, Ebrahimi, Z, Jahromi, ZK, Rahmati, Y, Sadri Nahand, J, Piroozmand, A, Jajarmi, V, et al
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022;:112743
Abstract
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral diseases. Here, we review the research progress in the use of CRISPR-Cas technology for treating viral infections, as well as the strategies for improving the delivery of this gene-editing tool in vivo. Key challenges that hinder the widespread clinical application of CRISPR-Cas9 technology are also discussed, and several possible directions for future research are proposed.
